Clinical trials: Venetoclax
Myeloid Malignancy, Acute Myeloid Leukemia
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants…
- Trial name
- NCT06129734
- Testing
- Venetoclax, Decitabine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Benjamin Tomlinson
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous…
- Trial name
- V-MIND (NCT05910801)
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Academic and Community Cancer Research United
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for…
- Conditions
- Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05807932
- Testing
- Venetoclax, Amsacrine, Ara-C
- Where
- 6 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Acute Myeloid Leukemia
Cladribine Venetoclax in Monocytic AML
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
- Trial name
- NCT06232655
- Testing
- Cladribine, Venetoclax, Azacitidine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Acute Myeloid Leukemia
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
The goal of this clinical study is to compare the effectiveness of the study drugs, magrolimab in combination with azacitidine, versus venetoclax in combination with azacitidine in participants with previously untreated TP53…
- Trial name
- ENHANCE-2 (NCT04778397)
- Testing
- Magrolimab, Venetoclax, Azacitidine
- Where
- 156 sites in United States, Australia and 13 more
- Volunteers
- 258 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to…
- Trial name
- NCT06536010
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Xiaotian